Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open‐label extension study

OBJECTIVE: This study was undertaken to evaluate the long‐term safety and effectiveness of fenfluramine in patients with Lennox–Gastaut syndrome (LGS). METHODS: Eligible patients with LGS who completed a 14‐week phase 3 randomized clinical trial enrolled in an open‐label extension (OLE; NCT03355209)...

Descripción completa

Detalles Bibliográficos
Autores principales: Knupp, Kelly G., Scheffer, Ingrid E., Ceulemans, Berten, Sullivan, Joseph, Nickels, Katherine C., Lagae, Lieven, Guerrini, Renzo, Zuberi, Sameer M., Nabbout, Rima, Riney, Kate, Agarwal, Anupam, Lock, Michael, Dai, David, Farfel, Gail M., Galer, Bradley S., Gammaitoni, Arnold R., Polega, Shikha, Davis, Ronald, Gil‐Nagel, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099582/
https://www.ncbi.nlm.nih.gov/pubmed/36196777
http://dx.doi.org/10.1111/epi.17431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099582/
https://www.ncbi.nlm.nih.gov/pubmed/36196777
http://dx.doi.org/10.1111/epi.17431

Ejemplares similares